---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-016001"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2025-09-29T23:59:59+00:00"
generated_at: "2026-05-17T05:26:00.727740+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Anebulo posts Q4 net loss $2.1M; starts Phase 1 IV selonabant; proposes reverse split for going private

## Summary
- Q4 FY2025 net loss of $2.1M ($0.05/shr) vs $1.3M ($0.05/shr) prior year; full-year net loss $8.5M ($0.25/shr) vs $8.2M ($0.32/shr).
- First subjects dosed in Phase 1 SAD study of IV selonabant for pediatric acute cannabis toxicity on September 25, 2025.
- Received year-2 NIDA/NIH grant of $994,300 to support the SAD study of IV selonabant.
- Board approved reverse stock split to reduce record holders below 300 as part of proposed going-private transaction; special meeting pending.
- Cash and cash equivalents $11.6M at June 30, 2025; additional $3M available under loan agreement.

## SEC filing metadata
- accession: 0001493152-25-016001
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2025-09-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315225016001/0001493152-25-016001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315225016001/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-016001
- JSON: https://secwatch.observer/filing/0001493152-25-016001.json
- Plain text: https://secwatch.observer/filing/0001493152-25-016001.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.